Geneviève Giraldeau
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Geneviève Giraldeau has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Daniel Juneau
Nuclear medicine division, Centre Hospitalier de l’Université de Montréal, Montréal, Canada
1 shared publication - François Harel
Department of Nuclear Medicine, Montreal Heart Institute and Université de Montréal, Montreal, Quebec, Canada
1 shared publication - Matthieu Pelletier-Galarneau
Department of Medical Imaging, Institut de Cardiologie de Montréal, Montréal, Canada
1 shared publication - Patrick Martineau
Department of Molecular Imaging and Therapy, BC Cancer, Vancouver, BC, Canada
1 shared publication - Stephanie Tan
Department of Radiology, Montreal Heart Institute, University of Montreal, Montreal, QC, Canada
1 shared publication - Yousif A. Lucinian
Department of Medical Imaging, Institut de Cardiologie de Montréal, Montréal, Canada
1 shared publication
Latest Publications
- 27 May 2026
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- p. 1-13
18F-fluorodeoxyglucose positron emission tomography and rest myocardial perfusion imaging in non-granulomatous myocarditis
Purpose Data on the use of fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) in non-granulomatous myocarditis are limited, and no study has evaluated the diagnostic performance of combined FDG-PET and rest myocardial perfusion imaging (rMPI). Methods We conducted a multicenter prospective observational feasibility study of patients who underwent combined FDG-PET/CT with rMPI as well as cardiac magnetic resonance (CMR) for suspected myocarditis. When available, endomyocardial biopsy (EMB) established the diagnosis according to consensus criteria. Otherwise, the final adjudicated clinical diagnosis served as the reference standard. All patients had a minimum follow-up of 12 months following PET imaging. Results Twenty-five patients were included, of whom 18 (72%) were diagnosed with myocarditis. FDG-PET and rMPI demonstrated a sensitivity/specificity of 61%/100%, and 59%/71%, respectively. Inter-reader agreement for FDG-PET was excellent (κ = 0.84, 95% CI 0.62–1.00). The combination of FDG-PET and rMPI yielded a sensitivity of 82% (95% CI: 50–93%) and a specificity of 71% (95% CI: 29–96%). Late gadolinium enhancement (LGE), excluding isolated subendocardial patterns, showed a sensitivity/specificity of 72%/57%. Spatial agreement between rMPI perfusion defects and LGE on CMR was modest (κ = 0.35, 95%CI: 0.23–0.47). Conclusion Combining FDG-PET with rMPI may be a feasible imaging modality for detecting non-granulomatous myocarditis by capturing both inflammatory and fibrotic components across different disease stages.
- 27 May 2026
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- p. 1-13
18F-fluorodeoxyglucose positron emission tomography and rest myocardial perfusion imaging in non-granulomatous myocarditis
Purpose Data on the use of fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) in non-granulomatous myocarditis are limited, and no study has evaluated the diagnostic performance of combined FDG-PET and rest myocardial perfusion imaging (rMPI). Methods We conducted a multicenter prospective observational feasibility study of patients who underwent combined FDG-PET/CT with rMPI as well as cardiac magnetic resonance (CMR) for suspected myocarditis. When available, endomyocardial biopsy (EMB) established the diagnosis according to consensus criteria. Otherwise, the final adjudicated clinical diagnosis served as the reference standard. All patients had a minimum follow-up of 12 months following PET imaging. Results Twenty-five patients were included, of whom 18 (72%) were diagnosed with myocarditis. FDG-PET and rMPI demonstrated a sensitivity/specificity of 61%/100%, and 59%/71%, respectively. Inter-reader agreement for FDG-PET was excellent (κ = 0.84, 95% CI 0.62–1.00). The combination of FDG-PET and rMPI yielded a sensitivity of 82% (95% CI: 50–93%) and a specificity of 71% (95% CI: 29–96%). Late gadolinium enhancement (LGE), excluding isolated subendocardial patterns, showed a sensitivity/specificity of 72%/57%. Spatial agreement between rMPI perfusion defects and LGE on CMR was modest (κ = 0.35, 95%CI: 0.23–0.47). Conclusion Combining FDG-PET with rMPI may be a feasible imaging modality for detecting non-granulomatous myocarditis by capturing both inflammatory and fibrotic components across different disease stages.